83 results about "Renal replacement therapy" patented technology

A system, method and apparatus for performing a renal replacement therapy is provided. In one embodiment, two small high flux dialyzers are connected in series. A restriction is placed between the two dialyzers in the dialysate flow path. The restriction is variable and adjustable in one preferred embodiment. The restriction builds a positive pressure in the venous dialyzer, causing a high degree of intentional backfiltration. That backfiltration causes a significant flow of dialysate through the high flux venous membrane directly into the patient's blood. That backfiltered solution is subsequently ultrafiltered from the patient from the arterial dialyzer. The diffusion of dialysate into the venous filter and removal of dialysate from the arterial dialyzer causes a convective transport of toxins from the patient. Additionally, the dialysate that does not diffuse directly into the patient but instead flows across the membranes of both dialyzers provides a diffusive clearance of waste products.

A continuous renal replacement therapy device adapted to be worn on a portion of the body of a patient, including: a plurality of contoured dialyzers, which are connected in series and utilize dialysate to remove impurities from the blood of the patient; and a plurality of contoured sorbent device, which are connected in series and are for regenerating the spent dialysate.

Systems and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system for performing kidney replacement therapy has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. The dialysis circuit and an extracorporeal circuit for circulating blood are in fluid communication through the dialysis membrane. The flux of fluid moving between the extracorporeal circuit and the dialysis circuit is modified by the rate at which the control pump is operating such that a rate of ultrafiltration and convective clearance can be controlled. The system provides for the monitoring of an inlet and outlet conductivity of the sorbent cartridge to provide a facility to quantify or monitor the removal of urea by the sorbent cartridge.

A cardiorenal patient monitoring system comprising, either implanted or non-implanted device(s), remote peripheral device(s), computer network(s), host, and communication means between the device(s), computer network(s), and host. The preferred embodiment shows an advanced patient monitoring system for using an implanted cardiac device and a dialysis machine in renal therapy. In addition, the method of advanced patient monitoring is in conjunction with the advanced patient monitoring system is disclosed.

A graphical user interface for a medical instruments for a Renal Replacement Therapy includes a pictogram representation of cthe fluid path of an extracorporeal blood circuit that represents fluid lines, pumps and sensors. To assist the user in responding to alarms and rectifying faults in the system the source of a potential trouble is animated. The location of a trouble spot is easily identified by flashing of the corresponding element of the pictogram, change of color or thickness of a corresponding line.

Apparatuses, systems, and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge, and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. A first sorbent cartridge is provided for use in a portable treatment module having activated carbon and zirconium oxide. The system also provides for the monitoring of an inlet and outlet conductivity of a sorbent cartridge containing urease to provide a facility to quantify or monitor the removal of urea by a detachable urea removal module.

A sterilized fluid management kit for use in renal replacement therapy isolates a replacement fluid container from touch contamination and provides for sterilization of replacement fluid by filtering using an installed filter that is hermetically connected to the replacement fluid container. A method is described where replacement fluid is automatically generated before treatment.

A flow loop for hemodialysis, hemodiafiltration and hemofiltration for the treatment of pathological conditions such as End Stage Renal Disease (ESRD) that has a controlled compliant flow path for preparing fluids required for a hemodialysis therapy session from water. The controlled compliant flow path modifies water into any one of a solution for priming a hemodialysis system, a physiologically compatible solution for contacting blood, a physiologically compatible solution for infusion to a subject, and a solution for blood rinse back to a subject. The controlled compliant flow path has a means for selectively metering in and metering out fluid from the flow path.

A method for renal replacement therapy includes priming a fluid circuit and recirculating the sterile fluid during priming to permit gas to float out of the sterile fluid into a fluid reservoir. The fluid is preferably either warmed during circulation or vibrated to promote the removal of gas.

Sorbent cartridges having a polystyrene sulfonate resin saturated with calcium ions for the performance of kidney replacement therapy are disclosed. Systems and methods having or using a sorbent cartridge, a dialyzer, control components, a cartridge having a polystyrene sulfonate resin, and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. A system for performing kidney replacement therapy has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. The system provides for the monitoring of an inlet and outlet conductivity of the sorbent cartridge to quantify or monitor the removal of urea by the sorbent cartridge.

The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and / or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP / BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.

A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and / or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed.

The present invention provides devices and methods for stabilizing bicarbonate-based solutions for peritoneal dialysis or hemofiltration. The bicarbonate-based solutions of the present invention are formulated and stored in at least two parts - an alkaline bicarbonate concentrate and an acidic concentrate. The alkaline bicarbonate concentrate is adjusted to have a pH of about 8.6 to 10.0. The acidic concentrate is adjusted to have a stable, acidic pH ranging from about 1.0 to 3.0. Upon mixing, although some variation in the pH of the mixed bicarbonate solution exists, the inventors have discovered that with the appropriate selection of the parameters of the concentrates, the pH of the mixed solution is always within an acceptable physiological range.

The invention contemplates transplacental enzyme replacement therapy (ERT) for deficiency of a polypeptide such as a tissue-nonspecific alkaline phosphatase (TNSALP) by administering a before-described pharmaceutical composition to a pregnant animal whose fetus or embryo is in need of such therapy. The fusion protein of such a composition comprises a water-soluble TNSALP portion, e.g., C-terminus-truncated TNSALP peptide-bonded to an IgG1 antibody Fc portion.The invention also contemplates a method for treating a metabolic disorder, such as HPP, in a fetus or embryo were a protein is administered to a pregnant mother. The fusion protein comprises a Fc fragment of an IgG1 antibody peptide-bonded to TNSALP. The protein crosses the placenta of the mother and enters the fetal blood stream. The protein is taken up into fetal tissue such that the TNSALP restores normal metabolic activity in the fetus.

The present invention relates to systems, methods and uses for recycling at least a part of water lost during various renal replacement therapy processes, e.g. in the preparation of a fresh dialysate solution or fresh reconstitution fluid for kidney disease dialysis and hemofiltration by utilizing water from the spent fluids. The system of the invention is useful in hemodialysis and in peritoneal dialysis as well as in hemofiltration for reuse of water from filtrates and spent fluids. In addition, the system of the invention is useful in the development of a renal assist device or artificial kidney.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein / bone morphogenetic protein (OP / BMP) family within the TGF-β superfamily of proteins.

The invention belongs to the field of blood purification and relates to a method for improving the regional citric acid anticoagulation, in particular to the method for improving the regional citric acid anticoagulation based on a mathematical model. The method comprises two stages of quantificational calculation of calcium supplement amounts for citric acid anticoagulation, namely, in the first stage, quantificationally calculating the sum of in-vitro circulation clearing amount and in-vivo accumulation amount of calcium, and in the second stage, quantificationally calculating the in-vitro circulation clearing amount of the calcium only required to be supplemented. By the method, the infusion speeds of the citric acid and the calcium during regional citric acid anticoagulation during continuous renal replacement therapy (CRRT) can be quantificationally calculated, and the application range of the regional citric acid anticoagulation is greatly expanded. Corresponding application and verification are performed on critical patients requiring regional citric acid anticoagulation CRRT treatment. A result shows that the method is safe and effective and can stabilize in-vivo and in-vitro accumulation ionized calcium level in a proper range; the service life of a filter is prolonged; and the monitoring times are obviously reduced.

The invention relates to a device for continuous renal replacement therapy (CRRT). The device comprises a blood loop, a blood purifier, a blood pump, a dialysate loop, a dialysate pump, a controller and a flow monitor; wherein the controller is used for adjusting a solution supply pump or a dewatering pump or uttering an alarm according to results of the flow monitor in monitoring of the dialysate loop. The problem that the accuracy of a CRRT machine in a volumetric metering technology is affected by multiple factors can be solved, and the constant and precise liquid flow can be ensured in the dialysate loop.

The invention relates to structural design of parts of a CRRT (continuous renal replacement therapy) machine, and in particular relates to an intelligent heparin pushing injector used for the CRRT machine. The intelligent heparin pushing injector comprises an injection syringe, a controller, a motor, a ball screw, an installation base plate, and a pushing base with an inner cavity, wherein a support base with a first groove in the bottom is fixedly arranged on the top of the installation base plate, and a through hole communicated with the first groove is formed in the bottom of the installation base plate; a fixed base is fixedly arranged on the top of the installation base plate, the pushing base is positioned between the support base and the fixed base, a nut of the ball screw is mounted in the inner cavity of the pushing base; a tube of the injection syringe is arranged on the top of the support base, the tail end of a handle of the injection syringe is connected with the pushing base, the output end of the motor extends towards the through hole, and is connected with the end, extending into the first groove of the support base, of a screw rod of the ball screw through a transmission mechanism, the controller is connected with the motor through a circuit to control the operation of the motor, and the nut of the ball screw drives the pushing base to push the tail end of the handle of the injection syringe to carry out pushing injection. The intelligent heparin pushing injector has the beneficial effects that the input speed is accurate to control and is stable, the operation is convenient, and the degree of automation is high.

The invention provides a portable and continuous kidney replacing therapy apparatus and a method for purifying blood. The therapy apparatus comprises a blood channel, a displacement liquid channel and an ultrafiltrate channel. The apparatus also comprises a first displacement pump, a second displacement pump and a controller, wherein, the first displacement pump is arranged in the displacement liquid channel, and liquid of fixed volume can be output per revolution; the second displacement pump is arranged in the ultrafiltrate channel, and liquid of fixed volume can be output per revolution; the controller calculates the input flow of the displacement liquid channel and the output flow of the ultrafiltrate channel in a volume metering method, controls the rotational speed of the first displacement pump and the second displacement pump and maintains the balance of the input flow and the output flow. The therapy apparatus of the invention can be used in the environments of turbulence, rocking and vibration, and the like, such as on the sea, and can be suitable for corrosion of salt-fog on the sea and a plurality of external power supplies.

The invention relates to the technical field of machine learning and to a method for predicting a heparin dosage in a continuous renal replacement therapy (CRPT) process, comprising the following steps: (1) installing relevant software and libraries; (2) analyzing and understanding the relevant information of a data set collected by a hospital; (3) preprocessing data; (4) extracting features, (5)determining a training set and a test set and processing unbalanced data; (6) predicting and evaluating a model; and (7) processing the abnormal values of predicted values. The method predicts the heparin dosage in the CRRT process by using a machine learning algorithm such as a gradient boosting regression model, and can give a reasonable and reliable heparin dosage reference value in the CRRT process by further processing the predicted value according to the trained model, thereby assisting the doctors, improving surgery quality, and achieving good economical efficiency and reliability.

A method as well as an apparatus is disclosed for determining the efficiency of a currently performed kidney replacement therapy on the dialysis side making use of a dialysis machine which in a first step is operated in a hemodialysis or hemodiafiltration process and in a second step is sequentially changed over to a hemofiltration process or is changed over to a sequential mode in which merely a flow from the blood compartment via the semipermeable membrane to the dialysis fluid compartment of the dialyser is generated in which, according to a third step, a sensor for determining or measuring the concentration at least of uremic toxins in the saturated dialysate or ultra-filtrate which is connected downstream of a dialyser on the dialysis side outputs corresponding measuring signals that are representative of the current concentration at least of uremic toxins in the blood to a calculation or determination unit.

The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.

The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).